Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung

NCT ID: NCT07202260

Last Updated: 2025-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-03

Study Completion Date

2028-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

By studying detailed patient data, researchers aim to find the best ways to treat these patients while reducing short- and long-term side effects. The findings will help refine radiotherapy treatments, ensuring they are as safe and effective as possible. Additionally, the results will provide doctors with better information to help patients understand the potential risks and benefits of their treatment options.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer (NSCLC) Lung Cancer (SCLC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with co-existing interstitial lung disease

No interventions assigned to this group

Patients who undergo radiotherapy twice to the same area (reirradiation).

No interventions assigned to this group

Patients with the less common or rare types of lung cancer

No interventions assigned to this group

Patients with cancer invading large blood vessels.

No interventions assigned to this group

Patients with oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Rare histology
* Disease invading vascular structures
* Co-existing interstitial lung disease (ILD)
* Radical re-irradiation
* Oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies.

Exclusion Criteria

* Include patients with stage IV disease who are receiving non-curative intent radiotherapy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Christie NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Christie NHS Foundation Trust

Withington, Greater Manchester, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CFTSP 230

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thoracic Tumours Register
NCT02941458 RECRUITING
99mTc-H7ND SPECT/CT Imaging in NSCLC
NCT05999214 RECRUITING NA